Trial Profile
Randomized Double Blind Placebo Controlled Trial of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 30 Aug 2022
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 01 Sep 2022 Results assessing the efficacy and safety of omalizumab in chinese and caucasian patients from chinese study (NCT01202903) and four studies with predominantly Caucasian patients (008, 009, EXTRA and INNOVATE) studies, published in the Asian Pacific Journal of Allergy and Immunology.
- 25 Feb 2019 Results presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 03 Apr 2018 Status changed from recruiting to completed.